ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis

Autor: Lani Lieberman, Beth Binnington, Nadine Shehata, Donald R. Branch, Emeralda Burke-Murphy, Jacob Pendergrast, Barbara Hannach, Katerina Pavenski, Vincent Laroche, Megan Blacquiere, Yulia Lin, Kezia Willie, Jiwajee Aziz, Jeannie Callum, Wendy Lau, Christine Cserti-Gazdewich, Jill R. Storry, Lorna Sampson Riden, Åsa Hellberg, Christine W. Bruggeman, Nagina Parmar, Darinka Sakac, Tik Nga Tong, Chantal Armali, Taco W. Kuijpers, Martin L. Olsson
Přispěvatelé: Paediatric Infectious Diseases / Rheumatology / Immunology, Landsteiner Laboratory, ARD - Amsterdam Reproduction and Development
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Zdroj: Blood, 131(7), 830-835. American Society of Hematology
ISSN: 0006-4971
DOI: 10.1182/blood-2017-07-796151
Popis: TO THE EDITOR: Although frequently effective[1][1],[2][2] and usually benign, high-dose (2 g/kg) intravenous immunoglobulin (IVIG) therapy can result in marked red blood cell (RBC) hemolysis, which in some cases is life threatening in severity.[3][3][⇓][4]-[5][5] The mechanism by which this
Databáze: OpenAIRE